Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 1/20 | 0.52 |
| ▸ | ATP4B | P51164 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.47 |
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13201562 | 0.87 | ATP4A (0.53) | ATP4AATP4BCYP19A1LMNA | |
| SCHEMBL14189706 | 0.85 | ATP4A (0.52) | ATP4AATP4BCYP19A1LMNAMEN1 | |
| SCHEMBL765017 | 0.84 | QPCT (0.56) | ATP4AATP4BCYP19A1DRD2DRD4 | |
| SCHEMBL18837867 | 0.84 | ATP4A (0.52) | ATP4AATP4BCYP19A1QPCTLMNA | |
| SCHEMBL22397927 | 0.84 | MEN1 (0.55) | ATP4AATP4BCYP19A1DRD2DRD3 | |
| SCHEMBL5564341 | 0.84 | ATP4A (0.52) | ATP4AATP4BCYP19A1LTA4HQPCT | |
| SCHEMBL10789116 | 0.82 | CYP19A1 (0.43) | ATP4AATP4BCYP19A1LTA4HNR5A1 | |
| SCHEMBL14996228 | 0.82 | ATP4A (0.53) | ATP4AATP4BCYP19A1LTA4HQPCT | |
| SCHEMBL5566302 | 0.81 | TBXAS1 (0.55) | ATP4AATP4BCYP19A1TBXAS1LMNA | |
| SCHEMBL16417747 | 0.81 | MEN1 (0.59) | ATP4AATP4BCYP19A1NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286426-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2025-04-29 | — | — | US | disclosed |
| EP-3704111-B1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2024-10-09 | — | — | EP | disclosed |
| CN-111886234-B | Heterocyclic mitochondrial activity inhibitors and uses thereof | 蒙特利尔大学 | 2023-12-15 | — | — | CN | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
| US-20210387980-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | Université de Montréal (CA) | 2021-12-16 | — | — | US | disclosed |
| CN-1930156-A | Oxidized thioether derivatives of styryl-azoles and their use as HER tyrosine kinases inhibitors | HOFFMANN LA ROCHE (CH) | 2007-03-14 | — | — | CN | disclosed |
| EP-1727815-A1 | ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-06 | — | — | EP | disclosed |
| EP-1725549-A1 | PENTAFLUOROSULFANYL COMPOUNDS, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| EP-1725551-A1 | OXIDIZED THIOETHER DERIVATIVES OF STYRYL-AZOLES AND THEIR USE AS HER TYROSINE KINASES INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005095393-A1 | OXIDIZED THIOETHER DERIVATIVES OF STYRYL-AZOLES AND THEIR USE AS HER TYROSINE KINASES INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095388-A1 | PENTAFLUOROSULFANYL COMPOUNDS, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005090338-A1 | ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| US-20050209290-A1 | Novel ether derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2005-09-22 | — | — | US | disclosed |
| US-20050203064-A1 | Novel oxidized thioether derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | US | disclosed |
| US-20050197370-A1 | Novel pentafluorosulfanyl compounds | HOFFMANN-LA ROCHE INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197370-A1 | Novel pentafluorosulfanyl compounds | SF3B5, SF3B1, SF3B3 | ATP4A 3018/4885ATP4B 2457/4885CYP19A1 635/4885 |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, IDH1 | ATP4A 1129/4885ATP4B 1452/4885CYP19A1 1319/4885 |
| US-20050203064-A1 | Novel oxidized thioether derivatives | SULT1E1, CYP4F3, GPX4 | ATP4A 1518/4885ATP4B 2077/4885CYP19A1 229/4885 |
| US-12286426-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, IDH1 | ATP4A 1129/4885ATP4B 1452/4885CYP19A1 1319/4885 |
| US-20210387980-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, NUTF2 | ATP4A 1802/4885ATP4B 2091/4885CYP19A1 1109/4885 |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, NUTF2 | ATP4A 1802/4885ATP4B 2091/4885CYP19A1 1109/4885 |
| US-20050209290-A1 | Novel ether derivatives | CYP2E1, CYP11B1, CYP11B2 | ATP4A 2125/4885ATP4B 2003/4885CYP19A1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.